| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 84016 |
Mal-amido-PEG8-Val-Gly (CAS: 2353409-54-6) |
226 |
WYQ |
2024-12-18 |
| 84017 |
(4E)-TCO-C3-PEG3-C3-amine |
112 |
zyl |
2024-12-18 |
| 84018 |
Fmoc-Ala-Pro-OH (CAS: 186023-44-9) |
203 |
WYQ |
2024-12-18 |
| 84019 |
BTP-7肽和细胞穿膜肽BR2共修饰的吲哚菁绿-米托蒽醌脂质体,BTP-7/BR2-ICG/MTO-LP |
245 |
axc |
2024-12-18 |
| 84020 |
Fmoc-PEG4-Val-Ala-PAB-PNP,N-芴甲氧羰基-四聚乙二醇-VAL-ALA-PAB-PNP |
101 |
kx |
2024-12-18 |
| 84021 |
Azide-PEG12-CH2CH2CH2-COOtBu |
130 |
zyl |
2024-12-18 |
| 84022 |
GNR-DOX-cRGD 阿霉素和cRGD共轭的金纳米棒 |
149 |
h |
2024-12-18 |
| 84023 |
Boc-Val-Cit-PAB-PNB(CAS:870487-10-8) |
152 |
WYQ |
2024-12-18 |
| 84024 |
MC (C5)-Val-Cit,CAS号:2504147-59-3 |
111 |
WYQ |
2024-12-18 |
| 84025 |
5-FAM-C3-SH |
178 |
zyl |
2024-12-18 |
| 84026 |
NOTA-gg Nle-CycMSHhex {(67)Ga-1,4,4DOTA-GGNle-CycMSHhex |
142 |
h |
2024-12-18 |
| 84027 |
cas:2353409-54-6 ,Mal-amido-PEG8-Val-Gly,马来酰亚胺-酰胺-八聚乙二醇-VAL-GLY |
162 |
kx |
2024-12-18 |
| 84028 |
MC-Val-Cit-PAB-OH(CAS:159857-80-4) |
170 |
WYQ |
2024-12-18 |
| 84029 |
叶酸靶向BQR-SS-DOX脂质体前药,BQR-SS-DOX/DSPE-PEG2000-FA,靶向脂质体定制服务 |
184 |
axc |
2024-12-18 |
| 84030 |
N3-C4-NHS ester,478801-48-8 |
132 |
zyl |
2024-12-18 |
| 84031 |
NOTA-GO 螯合剂NOTA偶联纳米石墨烯 |
157 |
h |
2024-12-18 |
| 84032 |
Fmoc-Ala-Ser(Psi(Me,Me)pro)-OH CAS:252554-78-2 |
112 |
WYQ |
2024-12-18 |
| 84033 |
CAS:863971-53-3,Fmoc-Val-Cit-PAB-PNP,抗体药物偶联物FMOC-VAL-CIT-PAB-PNP |
135 |
kx |
2024-12-18 |
| 84034 |
Cl-C6-PEG12-NHCO-C3-NHS,2727166-23-4烷基链 |
170 |
zyl |
2024-12-18 |
| 84035 |
PD-L1单抗修饰的尼洛替尼脂质体,LP-Nilotinib/αPDL1,αPDL1修饰的Nilotinib脂质体 |
187 |
axc |
2024-12-18 |
| 84036 |
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB CAS:2055042-69-6 |
146 |
WYQ |
2024-12-18 |
| 84037 |
Cl-C6-PEG9-NH2 hydrochloride-烷基链 |
111 |
zyl |
2024-12-18 |
| 84038 |
Fmoc-Val-Cit-PAB-OH CAS:159858-22-7 |
135 |
WYQ |
2024-12-18 |
| 84039 |
CAS:159857-80-4,MC-Val-Cit-PAB-OH ,MC-VAL-CIT-PAB中间体 |
116 |
kx |
2024-12-18 |
| 84040 |
Biotin-C6-amine,65953-56-2烷基链试剂 |
163 |
zyl |
2024-12-18 |
| 84041 |
鹿茸多肽脂质体水凝胶,Velvet,antler,peptides,liposome,hydrogel,VAP-Lip-Gel,脂质体纳米载体定制服务 |
153 |
axc |
2024-12-18 |
| 84042 |
NOTA-Bn-SCN-Aoc-BN(7-14)S-2-(4-异硫氰基苄基)-NOTA偶联BN(7-14) |
153 |
h |
2024-12-18 |
| 84043 |
CAS:2055048-57-0,Fmoc-PEG4-Ala-Ala-Asn-PAB ,芴甲氧羰基-四聚乙二醇-ALA-ALA ASN-PAB |
125 |
kx |
2024-12-18 |
| 84044 |
NH2-PEG3-C6-Cl,1261350-60-0 |
128 |
zyl |
2024-12-18 |
| 84045 |
MC-Val-Cit-PAB-PNP(CAS:159857-81-5) |
145 |
WYQ |
2024-12-18 |
| 84046 |
NOTA-HSA 大环配体NOTA偶联人血清白蛋白 |
112 |
h |
2024-12-18 |
| 84047 |
SPDP-Val-Cit-PAB-OH(N-琥珀酰亚胺基-3-(2-吡啶二硫)丙酸) |
99 |
WYQ |
2024-12-18 |
| 84048 |
鹿茸多肽脂质体,Velvet,antler,peptides,liposome,VAP-Lip,多功能载药脂质体定制服务 |
174 |
axc |
2024-12-18 |
| 84049 |
NOTA-西妥昔单抗-800CW NOTA-cetuximab-800CW |
111 |
h |
2024-12-18 |
| 84050 |
CAS:644981-35-1,Val-Cit-PAB-MMAE , ADC试剂 |
113 |
kx |
2024-12-18 |
| 84051 |
SPDP-Val-Cit-PAB-PNP,分子式:C33H39N7O9S2 |
134 |
WYQ |
2024-12-18 |
| 84052 |
Azido-PEG4-Ala-Ala-Asn(Trt)-PAB(CAS:2055042-67-4) |
183 |
WYQ |
2024-12-18 |
| 84053 |
负载黄芩苷脂质体的纳米纤维膜,BCL-LPs/PVA-CS,NFs,载药脂质体定制服务 |
201 |
axc |
2024-12-18 |
| 84054 |
Auristatin E(CAS:160800-57-7),澳瑞他汀E |
133 |
WYQ |
2024-12-18 |
| 84055 |
Amino-PEG10-C6 氨基-聚乙二醇10-C6 |
120 |
zyl |
2024-12-18 |
| 84056 |
2762519-08-2,endo-BCN-PEG4-Val-Cit-PAB-MMAE,(1R,8S,9S)-双环[6.1.0]壬-四聚乙二醇-VAL-CIT-PAB-MMAE |
110 |
kx |
2024-12-18 |
| 84057 |
MMAE(CAS:474645-27-7),一甲基澳瑞他汀E,Monomethyl auristatin E |
332 |
WYQ |
2024-12-18 |
| 84058 |
m-PEG1-C11-SH,117559-62-3,甲基-一聚乙二醇-C11-巯基 |
116 |
zyl |
2024-12-18 |
| 84059 |
CAS:1703768-74-4,Vipivotide tetraxetan Linker , ADC试剂 |
113 |
kx |
2024-12-18 |
| 84060 |
Thalidomide-O-Cn-NH2,沙利度胺-烷基链-氨基 |
125 |
zyl |
2024-12-18 |